Merus N.V.

NASDAQ:MRUS

65.56 (USD) • At close August 1, 2025
Bedrijfsnaam Merus N.V.
Symbool MRUS
Munteenheid USD
Prijs 65.56
Beurswaarde 4,882,692,452
Dividendpercentage 0%
52-weken bereik 33.19 - 67.59
Industrie Biotechnology
Sector Healthcare
CEO Dr. Sven Ante Lundberg M.D.
Website https://www.merus.nl

An error occurred while fetching data.

Over Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2

Vergelijkbare Aandelen

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

11.13 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

22.96 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.69 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

35.92 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

9.15 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

2.99 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

3.73 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

25.65 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)